Drug intelligence / Profile preview

HT-3951

Development stage: Discontinued
Lead developer: Dart NeuroScience
Modality: Small Molecules

Overview

HT-3951 is a small molecule drug developed by Dart NeuroScience. It acts as a selective inhibitor of monoamine oxidase B (MAO-B), an enzyme involved in the catabolism of neurotransmitters such as dopamine. By inhibiting MAO-B, HT-3951 increases dopamine levels in the brain, which may enhance memory formation and support motor recovery after neurological injury. The primary clinical development focus for HT-3951 was on improving upper extremity motor function following ischemic stroke. Clinical trials reached Phase 2 but were ultimately discontinued[1][2][3][6].

Targets

MAOB (Monoamine oxidase B)

Beyond the preview

Go deeper on HT-3951.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HT-3951.

Explore the full profile